Pathological complete response (pCR) rates following treatment are higher in BC patients with human epidermal growth factor receptor-2 positive (HER2+) or triple-negative (TN) relative to patients with HER2 negative (HER2−) or hormone receptor positive (HR+) disease. Here, ERBB2 is linked to breast cancer.